Side effects of qvar

Contents

Qvar

SIDE EFFECTS

Systemic and local corticosteroid use may result in the following:

  • Candida albicans infection
  • Immunosuppression
  • Hypercorticism and adrenal suppression
    • Growth effects
  • Glaucoma and cataracts

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The following reporting rates of common adverse experiences are based upon 4 clinical trials in which 1196 patients (671 female and 525 male adults previously treated with as-needed bronchodilators and/or inhaled corticosteroids) were treated with QVAR (doses of 40, 80, 160, or 320 mcg twice daily) or CFC-BDP (doses of 42, 168, or 336 mcg twice daily) or placebo. Table 3 below includes all events reported by patients taking QVAR (whether considered drug related or not) that occurred at a rate over 3% for QVAR. In considering these data, difference in average duration of exposure and clinical trial design should be taken into account.

Table 3 Adverse Events Reported by at Least 3% of the Patients for QVAR by Treatment and Daily Dose

Adverse
Events
Placebo
(N=289)
%
QVAR
Total
(N=624)
%
80-160
mcg
(N=233)
%
320
mcg
(N=335)
%
640
mcg
(N=56)
%
HEADACHE 9 12 15 8 25
PHARYNGITIS 4 8 6 5 27
UPPER RESP
TRACT
INFECTION
11 9 7 11 5
RHINITIS 9 6 8 3 7
INCREASED
ASTHMA
SYMPTOMS
18 3 2 4 0
ORAL SYMPTOMS
INHALATION
ROUTE
2 3 3 3 2
SINUSITIS 2 3 3 3 0
PAIN <1 2 1 2 5
BACK PAIN 1 1 2 <1 4
DYSPHONIA 2 <1 1 0 4

Other adverse events that occurred in these clinical trials using QVAR with an incidence of 1% to 3% and which occurred at a greater incidence than placebo were nausea, dysmenorrhea, and coughing. Oropharyngeal candidiasis occurred in <1% of patients in both QVAR and placebo treatment groups.

Pediatric Studies

In two 12-week placebo-controlled studies in steroid naive pediatric patients 5 to 12 years of age, no clinically relevant differences were found in the pattern, severity, or frequency of adverse events compared with those reported in adults, with the exception of conditions which are more prevalent in a pediatric population generally.

Postmarketing Experience

In addition to adverse reactions experienced in the clinical trials, the following adverse events have been reported during post-approval use of QVAR. Because they are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Local Effects: Localized infections with Candida albicans have occurred in patients treated with QVAR or other orally inhaled corticosteroids .

Psychiatric and Behavioral Changes: Aggression, depression, sleep disorders, psychomotor hyperactivity, and suicidal ideation have been reported (primarily in children).

Read the entire FDA prescribing information for Qvar (Beclomethasone Dipropionate HFA)

WARNINGS

Included as part of the “PRECAUTIONS” Section

PRECAUTIONS

Local Effects

Localized infections with Candida albicans have occurred in the mouth and pharynx in some patients receiving QVAR. If oropharyngeal candidiasis develops, it should be treated with appropriate local or systemic (i.e., oral) antifungal therapy while still continuing with QVAR therapy, but at times therapy with QVAR may need to be temporarily interrupted under close medical supervision. Rinsing the mouth after inhalation is advised.

Deterioration Of Asthma And Acute Episodes

QVAR is not indicated for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. An inhaled, short-acting beta-2 agonist, not QVAR, should be used to relieve acute symptoms such as shortness of breath. Instruct patients to contact their physician immediately if episodes of asthma that are not responsive to bronchodilators occur during the course of treatment with QVAR. During such episodes, patients may require therapy with oral corticosteroids.

Transferring Patients From Systemic Corticosteroid Therapy

Particular care is needed in patients who are transferred from systemically active corticosteroids to QVAR because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids. After withdrawal from systemic corticosteroids, a number of months are required for recovery of hypothalamic-pituitary-adrenal (HPA) function.

Patients who have been previously maintained on 20 mg or more per day of prednisone (or its equivalent) may be most susceptible, particularly when their systemic corticosteroids have been almost completely withdrawn. During this period of HPA suppression, patients may exhibit signs and symptoms of adrenal insufficiency when exposed to trauma, surgery, or infections (particularly gastroenteritis) or other conditions with severe electrolyte loss. Although QVAR may provide control of asthmatic symptoms during these episodes, in recommended doses it supplies less than normal physiological amounts of glucocorticoid systemically and does NOT provide the mineralocorticoid that is necessary for coping with these emergencies.

During periods of stress or a severe asthmatic attack, patients who have been withdrawn from systemic corticosteroids should be instructed to resume oral corticosteroids (in large doses) immediately and to contact their physician for further instruction. These patients should also be instructed to carry a warning card indicating that they may need supplementary systemic steroids during periods of stress or a severe asthma attack.

Patients requiring oral or other systemic corticosteroids should be weaned slowly from oral or other systemic corticosteroid use after transferring to QVAR. Lung function (FEV1 or PEF), beta-agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. In addition to monitoring asthma signs and symptoms, patients should be observed for signs and symptoms of adrenal insufficiency such as fatigue, lassitude, weakness, nausea and vomiting, and hypotension.

Transfer of patients from systemic corticosteroid therapy to QVAR may unmask allergic conditions previously suppressed by the systemic corticosteroid therapy, e.g., rhinitis, conjunctivitis, eczema, arthritis, and eosinophilic conditions.

During withdrawal from oral corticosteroids, some patients may experience symptoms of systemically active corticosteroid withdrawal, e.g., joint and/or muscular pain, lassitude, and depression, despite maintenance or even improvement of respiratory function.

Immunosuppression

Persons who are on drugs which suppress the immune system are more susceptible to infections than healthy individuals. Chickenpox and measles, for example, can have a more serious or even fatal course in non-immune children or adults on corticosteroids. In such children or adults who have not had these diseases or been properly immunized, particular care should be taken to avoid exposure. It is not known how the dose, route and duration of corticosteroid administration affects the risk of developing a disseminated infection. Nor is the contribution of the underlying disease and/or prior corticosteroid treatment known. If exposed to chickenpox, prophylaxis with varicella-zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If chickenpox develops, treatment with antiviral agents may be considered.

Inhaled corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infection of the respiratory tract; untreated systemic fungal, bacterial, parasitic or viral infections; or ocular herpes simplex.

Paradoxical Bronchospasm

Inhaled corticosteroids may produce inhalation induced bronchospasm with an immediate increase in wheezing after dosing that may be life-threatening. If inhalation induced bronchospasm occurs following dosing with QVAR, it should be treated immediately with an inhaled, short-acting bronchodilator. Treatment with QVAR should be discontinued and alternate therapy instituted.

Immediate Hypersensitivity Reactions

Hypersensitivity reactions, such as urticaria, angioedema, rash, and bronchospasm, may occur after administration of QVAR. Discontinue QVAR if such reactions occur

Hypercorticism And Adrenal Suppression

QVAR will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. Since beclomethasone dipropionate is absorbed into the circulation and can be systemically active at higher doses, the beneficial effects of QVAR in minimizing HPA dysfunction may be expected only when recommended dosages are not exceeded and individual patients are titrated to the lowest effective dose.

Because of the possibility of systemic absorption of inhaled corticosteroids, patients treated with QVAR should be observed carefully for any evidence of systemic corticosteroid effects. Particular care should be taken in observing patients postoperatively or during periods of stress for evidence of inadequate adrenal response.

It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression (including adrenal crisis) may appear in a small number of patients, particularly when beclomethasone dipropionate is administered at higher than recommended doses over prolonged periods of time. If such effects occur, the dosage of QVAR should be reduced slowly, consistent with accepted procedures for reducing systemic corticosteroids and for management of asthma symptoms.

Effects On Growth

Reduction In Bone Mineral Density

Glaucoma And Cataracts

Glaucoma, increased intraocular pressure, and cataracts have been reported following the use of longterm administration of inhaled corticosteroids. Therefore, close monitoring is warranted in patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts while using QVAR.

Patient Counseling Information

Advise the patients to read the FDA-approved patient labeling (PATIENT INFORMATION and Instructions for Use).

  • Risks Associated with Corticosteroid Therapy
    Local Effects: Advise patients that localized infections with Candida albicans have occurred in the mouth and pharynx in some patients. If oropharyngeal candidiasis develops, it should be treated with appropriate local or systemic (i.e., oral) antifungal therapy while still continuing with QVAR therapy, but at times therapy with QVAR may need to be temporarily interrupted under close medical supervision. Rinsing the mouth after inhalation is advised .
    Immunosuppression: Warn patients who are on immunosuppressant doses of corticosteroids to avoid exposure to chickenpox or measles and, if exposed, to consult their physician without delay. Inform patients of potential worsening of existing tuberculosis, fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex .
    Hypercorticism and Adrenal Suppression: Advise patients that QVAR may cause systemic corticosteroid effects of hypercorticism and adrenal suppression. Additionally, instruct patients that deaths due to adrenal insufficiency have occurred during and after transfer from systemic corticosteroids. Patients should taper slowly from systemic corticosteroids if transferring to QVAR .
    Reduction in Bone Mineral Density: Advise patients who are at an increased risk for decreased BMD that the use of corticosteroids may pose an additional risk and that they should be monitored and, where appropriate, be treated for this condition .
    Reduced Growth Velocity: Inform patients that orally inhaled corticosteroids, including QVAR, may cause a reduction in growth velocity when administered to pediatric patients. Physicians should closely follow the growth of pediatric patients taking corticosteroids by any route .
    Glaucoma and Cataracts: Long-term use of inhaled corticosteroids may increase the risk of some eye problems (glaucoma or cataracts); regular eye examinations should be considered .
  • Not for Acute Symptoms
    Advise patients that QVAR is not intended for use in the treatment of acute asthma. Acute asthma symptoms should be treated with an inhaled, short-acting beta-2 agonist such as albuterol. Instruct the patient to contact their healthcare provider immediately if there is any deterioration of their asthma .
  • Susceptibility to Infections
    Warn persons who are on immunosuppressant doses of corticosteroids to avoid exposure to chickenpox or measles and, if exposed, to consult their physician without delay. Inform patients of potential worsening of existing tuberculosis, fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex.
  • Use Daily for Best Effect
    Advise patients to use QVAR at regular intervals, since its effectiveness depends on regular use. Maximum benefit may not be achieved for 1 week or longer after starting treatment. If symptoms do not improve after 2 weeks of therapy or if the condition worsens, patients should be instructed to contact their physician.
  • Proper Use and Care of the Inhaler
    Priming: Priming is essential to ensure appropriate beclomethasone dipropionate content in each actuation. Instruct patients to prime the inhaler before using for the first time and in cases where the inhaler has not been used for more than 10 days by releasing two sprays into the air, away from the face.
    Cleaning: For normal hygiene, the mouthpiece of the inhaler should be cleaned weekly with a clean, dry tissue or cloth. DO NOT WASH OR PUT ANY PART OF THE INHALER IN WATER.
    Dose Counter: Inform patients that QVAR has a dose counter attached to the actuator. When the patient receives the inhaler, a black dot will appear in the viewing window until it has been primed 2 times, at which point the total number of actuations will be displayed. The dose counter will count down each time a spray is released. The dose-counter window displays the number of sprays left in the inhaler in units of two (e.g., 120, 118, 116, etc). When the counter displays 20, the color of the numbers will change to red to remind the patient to contact their pharmacist for a refill of medication or consult their physician for a prescription refill. When the dose counter reaches 0, the background will change to solid red. Inform patients to discard the QVAR inhaler when the dose counter displays 0 or after the expiration date on the product, whichever comes first.
  • Discontinuing QVAR
    Do not stop QVAR use abruptly. Instruct the patient to contact their healthcare provider immediately if use of QVAR is discontinued.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment Of Fertility

The carcinogenicity of beclomethasone dipropionate was evaluated in rats which were exposed for a total of 95 weeks, 13 weeks at inhalation doses up to 0.4 mg/kg/day and the remaining 82 weeks at combined oral and inhalation doses up to 2.4 mg/kg/day. There was no evidence of treatment-related increases in the incidence of tumors in this study at the highest dose, which is approximately 37 and 72 times the maximum recommended daily inhalation dose in adults and children, respectively, on a mg/m2 basis.

Beclomethasone dipropionate did not induce gene mutation in bacterial cells or mammalian Chinese Hamster ovary (CHO) cells in vitro. No significant clastogenic effect was seen in cultured CHO cells in vitro or in the mouse micronucleus test in vivo.

In rats, beclomethasone dipropionate caused decreased conception rates at an oral dose of 16 mg/kg/day (approximately 250 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis). Impairment of fertility, as evidenced by inhibition of the estrous cycle in dogs, was observed following treatment by the oral route at a dose of 0.5 mg/kg/day (approximately 25 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis). No inhibition of the estrous cycle in dogs was seen following 12 months of exposure to beclomethasone dipropionate by the inhalation route at an estimated daily dose of 0.33 mg/kg (approximately 17 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis).

Use In Specific Populations

Pregnancy

Pregnancy Category C

Risk Summary

There are no adequate and well-controlled studies with QVAR in pregnant women. Animal studies were conducted with beclomethasone dipropionate in rats, mice, and rabbits. Systemic exposure data were not determined in the animal studies. In rats exposed to beclomethasone dipropionate by inhalation at doses greater than 180 times the maximum recommended adult human daily inhalation dose (MRHDID), doserelated gross injury to the fetal adrenal glands was observed. However, there was no evidence of external or skeletal malformations or embryolethality in rats at inhalation doses up to 440 times the MRHDID. Beclomethasone dipropionate was teratogenic (mice and rabbits) and embryolethal (rabbits) at subcutaneous doses equal to or greater than approximately 0.75 times the MRHDID. Beclomethasone dipropionate treatment was embryolethal and caused decreased pup survival in mice at subcutaneous doses equal to or greater than 2.3 times the MRHDID. Beclomethasone dipropionate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Clinical Considerations

Disease-Associated Maternal and Fetal Risk

In women with poorly or moderately controlled asthma, evidence demonstrates that there is an increased risk of preeclampsia in the mother and prematurity, low birth weight and small for gestational age for the neonate. The level of asthma control should be closely monitored in pregnant women and treatment adjusted as necessary to maintain optimal control.

Animal Data

In an embryofetal development study in pregnant rats, beclomethasone dipropionate administration during organogenesis from gestation days 6 to 15 at inhaled doses 180 times the MRHDID (0.64 mg/day) in adults and higher (on a mg/m2 basis at maternal doses of 11.5 and 28.3 mg/kg/day) produced dosedependent gross injury (characterized by red foci) of the adrenalglands in fetuses. There were no findings in the adrenal glands of rat fetuses at an inhaled dose that was 40 times the MRHDID in adults(on a mg/m2 basis at a maternal dose of 2.4 mg/kg/day). There was no evidence of external or skeletal malformations or embryolethality in rat fetuses at inhaled doses up to 440 times the MRHDID (on a mg/m2 basis at maternal doses up to 28.3 mg/kg/day).

In an embryofetal development study in pregnant mice, beclomethasone dipropionate administration from gestation days 1 to 18 at subcutaneous doses equal to and greater than 0.75 times the MRHDID in adults (on a mg/m2 basis at maternal doses of 0.1 mg/kg/day and higher) produced teratogenic effects (increased incidence of cleft palate). A no effect dose in mice was not identified. In a second embryofetal development study in pregnant mice, beclomethasone dipropionate administration from gestation days 1 to 13 at subcutaneous doses equal to and greater than 2.3 times the MRHDID in adults (on a mg/m2 basis at a maternal dose of 0.3 mg/kg/day) produced embryolethal effects (increased fetal resorptions) and decreased pup survival.

In an embryofetal development study in pregnant rabbits, beclomethasone dipropionate administration during organogenesis from gestation days 7 to 16 at subcutaneous doses equal to and greater than 0.75 times the MRHDID in adults (on a mg/m2 basis at maternal doses of 0.025 mg/kg/day and higher) produced teratogenic (external and skeletal malformations) and embryolethal effects (increased fetal resorptions). There were no effects in fetuses of pregnant rabbits administered a subcutaneous dose 0.2 times the MRHDID in adults (on a mg/m2 basis at a maternal dose of 0.006 mg/kg/day).

Nursing Mothers

Corticosteroids are secreted in human milk. Caution should be exercised when QVAR is administered to a nursing mother.

Pediatric Use

Eight-hundred and thirty-four children between the ages of 5 and 12 were treated with HFA beclomethasone dipropionate (HFA-BDP) in clinical trials. The safety and effectiveness of QVAR in children below 5 years of age have not been established.

Use of QVAR with a spacer device in children less than 5 years of age is not recommended. In vitro dose characterization studies were performed with QVAR 40 mcg/actuation with the OptiChamber and AeroChamber Plus® spacer utilizing inspiratory flows representative of children under 5 years old. These studies indicated that the amount of medication delivered through the spacing device decreased rapidly with increasing wait times of 5 to 10 seconds as shown in Table 4. If QVAR is used with a spacer device, it is important to inhale immediately.

Based on the average inspiratory flow rates generated by children 6 months to 5 years old, the projected daily dose derived from QVAR 40 mcg at one puff per day at various wait times is depicted in Table 4 below:

Table 4 – Average Daily Dose Based on Wait Time in Pediatric Patients

Wait time, seconds Mean medication delivery through Aero Chamber mcg/actuation* i Body Weight 50th percentile, kg† ii Medication delivered per dose, mcg/kg‡ iii§ iv
Age 6 months, Flow rate 4.8 L/min 0 11.5 7.6 1.2
Age 2 years, Flow rate 8.2 L/min 0 14.1 13.5 0.83
Age 2 years,
Flow rate
8.2 L/min
5 5.4 13.5 0.32
Age 2 years,
Flow rate
8.2 L/min
10 3.9 13.5 0.23
Age 5 years,
Flow rate
11.0 L/min
0 17.5 18 0.78
*Summary Report; Pediatric Dose Characterization of QVAR with Spacer; 3M Pharmaceutical Development, July 21, 2004
†CDC Growth charts, developed by the National Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).
‡Includes an estimated 20% loss in the masks\
§QVAR 4 0mcg in an average adult without using a spacer delivers approximately 0.4 mcg/kg, or bid, 0.8 mcg/kg/day.

Controlled clinical studies have shown that inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients. A 12-month, randomized, controlled clinical trial evaluated the effects of HFA beclomethasone dipropionate without spacer versus CFC beclomethasone dipropionate with large-volume spacer on growth in children age 5 to 11. A total of 520 patients were enrolled, of whom 394 received HFA-BDP (100 to 400 mcg/day ex-valve) and 126 received CFC-BDP (200 to 800 mcg/day ex-valve). Similar control of asthma was noted in each treatment arm. When comparing results at month 12 to baseline, the mean growth velocity in children treated with HFA-BDP was approximately 0.5 cm/year less than that noted with children treated with CFC-BDP via large-volume spacer. The long-term effects of the reduction in growth velocity associated with orally inhaled corticosteroids, including the impact on final adult height, are unknown. The potential for “catch-up” growth following discontinuation of treatment with orally inhaled corticosteroids has not been adequately studied.

The growth of children and adolescents receiving orally inhaled corticosteroids, including QVAR, should be monitored routinely (e.g., via stadiometry). If a child or adolescent on any corticosteroid appears to have growth suppression, the possibility that he/she is particularly sensitive to this effect should be considered. The potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the risks associated with alternative therapies. To minimize the systemic effects of orally inhaled corticosteroids, including QVAR, each patient should be titrated to his/her lowest effective dose .

Geriatric Use

Clinical studies of QVAR did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Qvar Redihaler

Generic Name: beclomethasone inhalation (be kloe METH a sone)
Brand Name: Qvar, Qvar Redihaler

Medically reviewed by Drugs.com on Oct 15, 2019 – Written by Cerner Multum

  • Overview
  • Side Effects
  • Dosage
  • Interactions
  • Pregnancy
  • More

What is Qvar Redihaler?

Beclomethasone is a steroid. It prevents the release of substances in the body that cause inflammation.

Qvar Redihaler is used to prevent asthma attacks in adults and children who are at least 5 years old. This medication will not treat an asthma attack that has already begun.

Qvar Redihaler may also be used for purposes not listed in this medication guide.

Important Information

Qvar Redihaler will not work fast enough to treat an asthma attack. Use only a fast acting inhalation medicine for an asthma attack.

Before taking this medicine

You should not use beclomethasone if you are allergic to it.

To make sure Qvar Redihaler is safe for you, tell your doctor if you have ever had:

  • any type of bacterial, fungal, or viral infection;

  • active tuberculosis infection that is not being treated;

  • herpes infection of the eyes;

  • osteoporosis, or low bone mineral density;

  • a weak immune system; or

  • cataracts, glaucoma, or increased pressure inside your eyes.

It is not known whether this medicine will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.

Beclomethasone inhalation can pass into breast milk and may harm a nursing baby. You should not breast-feed while using this medicine.

Beclomethasone should not be given to a child younger than 5 years old.

How should I use Qvar Redihaler?

Follow all directions on your prescription label. Do not use this medicine in larger or smaller amounts or for longer than recommended.

Beclomethasone is not a rescue medicine. It will not work fast enough to treat an asthma attack. Use only a fast-acting asthma medicine for an attack. Tell your doctor if it seems like your asthma medications don’t work as well.

Follow all patient instructions for safe and effective use, and directions for priming the inhaler device. Prime the inhaler device before the first use by pumping 2 test sprays into the air, away from your face. Prime the inhaler if it has not been used for longer than 10 days.

To reduce the chance of developing a yeast infection, rinse your mouth with water after using beclomethasone. Do not swallow.

Do not wash your inhaler device or allow it to get wet. Wipe the mouthpiece with a clean dry tissue or cloth at least once per week.

Your inhaler device may have a dose counter to show how many sprays are left in the canister. Check this number often. When the number reaches 0, there are no sprays left. Get your prescription refilled before you run out of medicine completely.

Always use the new device provided with the medicine when you get your prescription filled.

It may take 1 to 2 weeks or longer before your symptoms improve. Keep using the medication as directed and call your doctor if your symptoms do not begin to improve after 2 weeks of treatment.

Your dose needs may change if you have surgery, are ill, are under stress, or have recently had an asthma attack. Do not change your medication dose or schedule without your doctor’s advice.

Asthma is usually treated with a combination of drugs. Use all medications as directed by your doctor. Seek medical attention if you think your asthma medications are not working as well. An increased need for medication could be an early sign of a serious asthma attack.

You should not stop using Qvar Redihaler suddenly. If you switched to this medicine from an oral (taken by mouth) steroid, do not stop using the other steroid suddenly or you may have unpleasant withdrawal symptoms. Follow your doctor’s instructions about tapering your dose.

You may need to restart the oral steroid if you are under stress or have an asthma attack or other medical emergency. Wear a medical alert tag or carry an ID card stating that you may need an oral steroid in an emergency.

Beclomethasone can weaken your immune system. Your blood may need to be tested often.

Store at room temperature away from moisture and heat. Store the inhaler device with the canister upright and the mouthpiece on top. Keep the canister away from open flame or high heat, such as in a car on a hot day. The canister may explode if it gets too hot. Do not puncture or burn an empty inhaler canister.

What happens if I miss a dose?

Use the medicine as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not use extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while using Qvar Redihaler?

Rinse with water if Qvar Redihaler gets in your eyes.

Avoid being near people who are sick or have infections. Call your doctor for preventive treatment if you are exposed to chicken pox or measles. These conditions can be serious or even fatal in people who are using steroid medication.

Qvar Redihaler side effects

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Beclomethasone can affect growth in children. Talk with your doctor if you think your child is not growing at a normal rate while using this medicine.

Call your doctor at once if you have:

  • wheezing, choking, or other breathing problems after using this medication;

  • worsening asthma symptoms;

  • white patches or sores inside your mouth or on your lips;

  • blurred vision, tunnel vision, eye pain, or seeing halos around lights;

  • signs of infection–fever, chills, body aches, vomiting; or

  • signs of low adrenal gland hormones–worsening tiredness, lack of energy, weakness, feeling light-headed, nausea, vomiting.

Common side effects may include:

  • a yeast infection in the mouth;

  • headache;

  • sore throat; or

  • runny nose, sinus pain, irritation in your nose.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Qvar Redihaler?

Other drugs may interact with beclomethasone inhalation, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Further information

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Copyright 1996-2018 Cerner Multum, Inc. Version: 11.01.

Medical Disclaimer

More about Qvar RediHaler (beclomethasone)

  • Side Effects
  • During Pregnancy or Breastfeeding
  • Dosage Information
  • Drug Interactions
  • Pricing & Coupons
  • En Español
  • 62 Reviews
  • Drug class: inhaled corticosteroids

Consumer resources

  • Qvar RediHaler
  • Qvar Redihaler (Advanced Reading)

Other brands: Qvar, Beclovent

Professional resources

  • Beclomethasone Dipropionate (AHFS Monograph)

Related treatment guides

  • Asthma, Maintenance

QVAR

beclomethasone dipropionate aerosol, metered

Get an overview of QVAR (beclomethasone dipropionate aerosol, metered), including its generic name, formulation (i.e. pill, oral solution, injection, inhaled medicine) and why it’s used. The medication in QVAR can be sold under different names.
Refer to the “Also Known As” section to reference different products that include the same medication as QVAR.

Drug Basics

Brand Name: QVAR

Generic Name: BECLOMETHASONE DIPROPIONATE

Drug Type: HUMAN PRESCRIPTION DRUG

Route: RESPIRATORY (INHALATION)

Dosage Form: AEROSOL, METERED

Data Current As Of: 2018-10-05

recent major changes

QVAR® is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older.

Important Limitations of Use:

  • QVAR is NOT indicated for the relief of acute bronchospasm.

patient counseling information

Advise the patients to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Risks Associated with Corticosteroid Therapy

  • Local Effects: Advise patients that localized infections with Candida albicans have occurred in the mouth and pharynx in some patients. If oropharyngeal candidiasis develops, it should be treated with appropriate local or systemic (i.e., oral) antifungal therapy while still continuing with QVAR therapy, but at times therapy with QVAR may need to be temporarily interrupted under close medical supervision. Rinsing the mouth with water without swallowing after inhalation is advised .
  • Immunosuppression: Warn patients who are on immunosuppressant doses of corticosteroids to avoid exposure to chickenpox or measles and, if exposed, to consult their physician without delay. Inform patients of potential worsening of existing tuberculosis, fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex .
  • Hypercorticism and Adrenal Suppression: Advise patients that QVAR may cause systemic corticosteroid effects of hypercorticism and adrenal suppression. Additionally, instruct patients that deaths due to adrenal insufficiency have occurred during and after transfer from systemic corticosteroids. Patients should taper slowly from systemic corticosteroids if transferring to QVAR .
  • Reduction in Bone Mineral Density: Advise patients who are at an increased risk for decreased BMD that the use of corticosteroids may pose an additional risk and that they should be monitored and, where appropriate, be treated for this condition .
  • Reduced Growth Velocity: Inform patients that orally inhaled corticosteroids, including QVAR, may cause a reduction in growth velocity when administered to pediatric patients. Physicians should closely follow the growth of pediatric patients taking corticosteroids by any route .
  • Eye Disorders: Long-term use of inhaled corticosteroids may increase the risk of some eye problems (glaucoma, cataracts, blurred vision); regular eye examinations should be considered .

Not for Acute Symptoms

  • Advise patients that QVAR is not intended for use in the treatment of acute asthma. Acute asthma symptoms should be treated with an inhaled, short-acting beta-2 agonist such as albuterol. Instruct the patient to contact their healthcare provider immediately if there is any deterioration of their asthma .

Susceptibility to Infections

  • Warn persons who are on immunosuppressant doses of corticosteroids to avoid exposure to chickenpox or measles and, if exposed, to consult their physician without delay. Inform patients of potential worsening of existing tuberculosis, fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex .

Use Daily for Best Effect

  • Advise patients to use QVAR at regular intervals, since its effectiveness depends on regular use. Maximum benefit may not be achieved for 1 week or longer after starting treatment. If symptoms do not improve after 2 weeks of therapy or if the condition worsens, patients should be instructed to contact their physician.

Proper Use and Care of the Inhaler

  • Priming: Priming is essential to ensure appropriate beclomethasone dipropionate content in each actuation. Instruct patients to prime the inhaler before using for the first time and in cases where the inhaler has not been used for more than 10 days by releasing two sprays into the air, away from the face.
  • Cleaning: For normal hygiene, the mouthpiece of the inhaler should be cleaned weekly with a clean, dry tissue or cloth. DO NOT WASH OR PUT ANY PART OF THE INHALER IN WATER.
  • Dose Counter: Inform patients that QVAR has a dose counter attached to the actuator. When the patient receives the inhaler, a black dot will appear in the viewing window until it has been primed 2 times, at which point the total number of actuations will be displayed. The dose counter will count down each time a spray is released. The dose-counter window displays the number of sprays left in the inhaler in units of two (e.g., 120, 118, 116, etc). When the counter displays 20, the color of the numbers will change to red to remind the patient to contact their pharmacist for a refill of medication or consult their physician for a prescription refill. When the dose counter reaches 0, the background will change to solid red. Inform patients to discard the QVAR inhaler when the dose counter displays 0 or after the expiration date on the product, whichever comes first.
  • Discontinuing QVAR
  • Do not stop QVAR use abruptly. Instruct the patient to contact their healthcare provider immediately if use of QVAR is discontinued.

Rx only

Marketed By:

Teva Respiratory, LLC

Frazer, PA 19355

Developed And Manufactured By:

3M Drug Delivery Systems

Northridge, CA 91324

and/or

3M Health Care, Ltd.

Loughborough, UK

© 2017 Teva Respiratory, LLC

QVAR® is a registered trademark of IVAX LLC, a member of the Teva Group.

United States Patent Nos. 6,446,627 and 9,463,289

OptiChamber is a registered trademark of Respironics Healthscan, Inc. and AeroChamber Plus is a registered trademark of Trudell Medical International Trudell Partnership Holdings Limited and Packard Medical Supply Centre Ltd.

QVA-003

Attention Pharmacist: Detach “Patient Information and Instructions for Use” from package insert and dispense with the product.

Patient Information

QVAR® (Kyu-var)

(beclomethasone dipropionate HFA)

inhalation aerosol

What is QVAR?

QVAR is an inhaled prescription medicine used as a maintenance treatment for the prevention and control of asthma in people 5 years of age and older.

  • QVAR is not used to relieve sudden breathing problems.

It is not known if QVAR is safe and effective in children less than 5 years of age.

Who should not use QVAR?

Do not use QVAR:

  • to treat sudden severe symptoms of asthma.
  • as a rescue inhaler.
  • if you are allergic to beclomethasone dipropionate or any of the ingredients in QVAR. See the end of this leaflet for a complete list of ingredients in QVAR.

What should I tell my healthcare provider before using QVAR?

Before using QVAR, tell your healthcare provider about all of your medical conditions, including if you:

  • are exposed to chickenpox or measles
  • have or have had tuberculosis (TB) or any untreated fungal, bacterial or viral infections, or eye infections caused by herpes.
  • have weak bones (osteoporosis).
  • have an immune system problem
  • have or have had eye problems, such as blurred vision, increased pressure in your eye (glaucoma), or cataracts.
  • are pregnant or plan to become pregnant. It is not known if QVAR will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if QVAR passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you use QVAR.

Tell your healthcare provider about all of the medications you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I use QVAR?

Read the step-by-step instructions for using QVAR at the end of this Patient Information leaflet.

  • Use QVAR exactly as your healthcare provider tells you to. Do not use QVAR more often than it is prescribed.
  • Do not change or stop using QVAR or other asthma medicines used to treat your breathing problems unless your healthcare provider tells you to. Your healthcare provider will change your medicines as needed.
  • You must use QVAR regularly. It may take 1 to 4 weeks, or longer, after you start using QVAR for your asthma symptoms to get better. Do not stop using QVAR, even if you are feeling better, unless your healthcare provider tells you to.
  • QVAR comes in 2 strengths (40 and 80 mcg). Your healthcare provider has prescribed the strength that is best for you. Pay attention to the differences between QVAR and your other inhaled medicines, including their prescribed use and the way they look.
  • QVAR does not relieve sudden asthma symptoms. Always have a rescue inhaler with you to treat sudden symptoms. Use your rescue inhaler if you have breathing problems between doses of QVAR. If you do not have a rescue inhaler, call your healthcare provider to have a rescue inhaler prescribed for you.
  • Rinse your mouth with water without swallowing after each dose of QVAR. This will help lessen the chance of getting a yeast infection (thrush) in your mouth and throat.
  • Do not spray QVAR in your face or eyes. If you accidentally get QVAR in your eyes, rinse your eyes with water and if redness or irritation continues, call your healthcare provider.

What should I avoid while using QVAR?

If you have not had, or have not been vaccinated against, chickenpox or measles, you should stay away from people who are infected.

What are the possible side effects of QVAR?

QVAR may cause serious side effects, including:

  • fungal infections (thrush) in your mouth and throat. You may develop a yeast infection (Candida albicans) in your mouth and throat.Tell your healthcare provider if you have any redness or white colored patches in your mouth or throat. Rinse your mouth with water without swallowing after using QVAR to help prevent an infection in your mouth or throat.
  • worsening asthma or sudden asthma attacks. You should contact your healthcare provider right away if you do not get relief from your sudden asthma attacks, after using your rescue inhaler, during your treatment with QVAR.
  • reduced adrenal function (adrenal insufficiency). Adrenal insufficiency that can lead to death can happen when you stop taking oral corticosteroid medicines and start using inhaled corticosteroid medicines. Adrenal insufficiency can also happen in people who take higher doses of QVAR than recommended over a long period of time. When your body is under stress such as from fever, trauma (such as a car accident), infection, or surgery, adrenal insufficiency can get worse. Signs and symptoms of adrenal insufficiency may include:
  • feeling tired or exhausted (fatigue)
  • lack of energy
  • weakness
  • dizziness or feeling faint
  • nausea and vomiting
  • low blood pressure (hypotension)
  • immune system effects and a higher chance for infections. Tell your healthcare provider about any signs or symptoms of infection such as:
    • fever
    • pain
    • body aches
    • chills
    • feeling tired
    • nausea
    • vomiting
  • increased wheezing (bronchospasm) right after using QVAR. Always have a rescue inhaler with you to treat sudden wheezing.
  • serious allergic reactions. Stop using QVAR and call your healthcare provider or get emergency medical help right away if you get any of the following signs or symptoms of an serious allergic reaction:
    • hives
    • swelling of your lips, tongue, or face
    • rash
    • breathing problems
  • slowed growth in children. Children should have their growth checked regularly while using QVAR.
  • lower bone density. This may be a problem for people who already have a higher chance for low bone density (osteoporosis).
  • eye problems. If you have had glaucoma, cataracts or blurred vision in the past, you should have regular eye exams while using QVAR.

The most common side effects of QVAR include:

  • headache
  • throat irritation (pharyngitis)
  • sinus irritation (sinusitis)

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of QVAR. Ask your healthcare provider or pharmacist for more information.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store QVAR?

  • Store QVAR at room temperature between 68ºF to 77ºF (20ºC to 25ºC).
  • Your QVAR canister should only be used with the QVAR actuator. Do not use any other medicines in your QVAR actuator.
  • The contents of your QVAR canister are under pressure. Do not puncture the QVAR canister.
  • Do not store your QVAR canister near heat or a flame. Temperatures above 120ºF may cause the canister to burst.
  • Do not throw your QVAR canister into a fire or incinerator.
  • When not in use, store QVAR so that the product rests on the concave end of the canister with the plastic actuator on top.

Keep QVAR and all medicines out of the reach of children.

General information about the safe and effective use of QVAR.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use QVAR for a condition for which it was not prescribed. Do not give QVAR to other people, even if they have the same symptoms that you have. It may harm them.

You can ask your pharmacist or healthcare provider for information about QVAR that is written for health professionals.

What are the ingredients in QVAR?

Active ingredient: beclomethasone dipropionate

Inactive ingredients: propellant HFA-134a and ethanol

For more information, go to www.QVAR.com or call 1-888-482-9522.

QVAPL-003

Instructions for Use

QVAR (Kyu-var)

(beclomethasone dipropionate HFA)

inhalation aerosol

It is important that you read these instructions before using QVAR.

Correct and regular use of the inhaler will prevent or lessen the severity of asthma attacks.

  • Do not use the QVAR actuator with a canister of medicine from any other inhaler.
  • Do not use a QVAR canister with an actuator from any other inhaler, including another QVAR inhaler.

The parts of your QVAR:

  • There are 2 main parts of your QVAR inhaler including the:
  • metal canister that holds the medicine (See Figure A)
  • plastic actuator that sprays the medicine from the canister (See Figure A)
  • Figure A
  • The inhaler has a cap that covers the mouthpiece of the actuator to protect it from dust (See Figure A). The cap should be removed before use.
    • The inhaler comes with a dose counter located on the back of the actuator (See Figure B). The dose counter window will show you the number of actuations (puffs) of medicine remaining in units of 2. The inhaler contains “120” actuations (puffs).

Figure B

  • The first time you use QVAR inhaler, the dose counter will show “120” actuations remaining (See Figure B). Each time you press the metal canister, a puff of medicine is released and the dose counter will count down.
  • When the dose counter reaches 0, it will continue to show 0 and you should replace your QVAR inhaler.
  • The dose counter cannot be reset and is permanently attached to the actuator. Never change the numbers for the dose counter or touch the pin inside the actuator.

Do not remove the metal canister from the plastic actuator.

Before using your QVAR inhaler:

Remove the cap from the mouthpiece of the actuator (See Figure C). Check the mouthpiece for objects before use. Make sure the metal canister is fully inserted into the actuator.

Figure C

Priming your QVAR inhaler:

Before you use your QVAR inhaler for the first time or if you have not used your QVAR Inhaler for more than 10 days, you will need to prime your QVAR Inhaler.

  • Before priming, the inhaler will show a black dot in the dose counter window (See Figure D).

Figure D

  • Hold the QVAR Inhaler in the upright position and with the mouthpiece pointing away from you.
  • Press down on the metal canister 2 times and release 2 actuations (puffs) into the air and away from your face.
  • After priming 2 times, the dose counter should read “120.”
    • Your QVAR Inhaler is now ready to use.

Using your QVAR inhaler:

Step 1: Remove the cap from the mouthpiece of the actuator (See Figure C).Check the mouthpiece for objects before use. Make sure the metal canister is fully inserted into the actuator.

  • Step 2: Breathe out as fully as you comfortably can. Hold the inhaler in the upright position (See Figure E). Close your lips around the mouthpiece, keeping your tongue below it.
  • Figure E
  • Step 3: While breathing in deeply and slowly, press down on the metal canister with your finger (See Figure E). When you have finished breathing in, hold your breath as long as you comfortably can (5 to 10 seconds).
  • Step 4: Take your finger off the metal canister and remove the inhaler from your mouth. Breathe out gently.

If your healthcare provider has told you to take more than 1 inhalation per dose, repeat steps 1 through 4.

  • After using your QVAR inhaler:
  • Replace the cap over the mouthpiece right away after use.
  • You should rinse your mouth with water without swallowing after you finish using QVAR.
  • Clean the mouthpiece of your QVAR inhaler weekly with a clean, dry tissue or cloth.
  • Do not wash or put any part of your inhaler in water.

When to replace your QVAR Inhaler:

  • It is important that you pay attention to the number of actuations (puffs) left in your QVAR inhaler by reading the dose counter.
  • When the dose counter on the actuator reads “20”, the color of the number will change to red and you should refill your prescription or ask your healthcare provider if you need another prescription for QVAR Inhaler.
  • When the dose counter reaches “0”, the background color in the dose counter window will change to solid red. Throw away your QVAR inhaler as soon as the dose counter reads “0” or by the expiration date on the QVAR Inhaler package, whichever comes first.
  • Do not use QVAR past the expiration date.

This Patient Information and Instructions for Use has been approved by the U.S. Food and Drug Administration.

Marketed By:

Teva Respiratory, LLC

  • Frazer, PA 19355

Developed And Manufactured By:

3M Drug Delivery Systems AND/OR 3M Health Care, Ltd.

  • Northridge, CA 91324 Loughborough, UK

© 2017 Teva Respiratory, LLC

QVAR is a registered trademark of IVAX LLC, a member of the TEVA Group.

QVAIFU-003

Revised: 09/2017

beclomethasone dipropionate

also known as

This drug label information is as submitted to the Food and Drug Administration (FDA) and is intended for informational purposes only. If you think you may have a medical emergency, immediately call your doctor or dial 911. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

What is Qvar?

Inhaled corticosteroids will not relieve an asthma attack that has already started. However, your doctor may want you to continue taking this medicine at the usual time, even if you use another medicine to relieve the asthma attack.

Use this medicine only as directed. Do not use more of it and do not use it more often than your doctor ordered. To do so may increase the chance of side effects. Do not stop taking this medicine abruptly. This medicine should be discontinued only under the supervision of your doctor.

In order for this medicine to help prevent asthma attacks, it must be used every day in regularly spaced doses, as ordered by your doctor. Up to 4 to 6 weeks may pass before you begin to notice improvement in your condition. It may take several months before you feel the full effects of this medicine. This may not take as long if you have already been taking certain other medicines for your asthma.

Gargling and rinsing your mouth with water after each dose may help prevent hoarseness, throat irritation, and infection in the mouth. However, do not swallow the water after rinsing. Your doctor may also want you to use a spacer device to lessen these problems.

Inhaled corticosteroids are used with a special inhaler and usually come with patient directions. Read the directions carefully before using this medicine. If you do not understand the directions or you are not sure how to use the inhaler, ask your health care professional to show you what to do. Also, ask your health care professional to watch how you use the inhaler to make sure you are using it properly.

For patients using beclomethasone, flunisolide, or triamcinolone inhalation aerosol:

  • When you use the inhaler for the first time, or if you have not used it in a while, it may not deliver the right amount of medicine with the first puff. So, before using the inhaler, test or prime it.
  • To test or prime most inhalers:
    • Insert the metal canister firmly into the clean mouthpiece according to the manufacturer’s instructions. Check to make sure the canister is placed properly into the mouthpiece.
    • Take the cover off the mouthpiece and shake the inhaler three or four times.
    • Hold the inhaler well away from you at arm’s length and press the top of the canister, spraying the medicine into the air two times. The inhaler will now be ready to provide the right amount of medicine when you use it.
  • To use most inhalers:
    • Using your thumb and one or two fingers, hold the inhaler upright with the mouthpiece end down and pointing toward you.
    • Take the cover off the mouthpiece. Check the mouthpiece and remove any foreign objects. Then gently shake the inhaler three or four times.
    • Hold the mouthpiece away from your mouth and breathe out slowly to the end of a normal breath.
    • Use the inhalation method recommended by your doctor:
      • Open-mouth method—Place the mouthpiece about 1 or 2 inches (2 finger widths) in front of your widely opened mouth. Make sure the inhaler is aimed into your mouth so that the spray does not hit the roof of your mouth or your tongue.
      • Closed-mouth method—Place the mouthpiece in your mouth between your teeth and over your tongue with your lips closed tightly around it. Do not block the mouthpiece with your teeth or tongue.
    • Start to breathe in slowly through your mouth and, at the same time, press the top of the canister one time to get 1 puff of medicine. Continue to breathe in slowly for 3 to 5 seconds. Count the seconds while inhaling. It is important to press the top of the canister and breathe in slowly at the same time so the medicine gets into your lungs. This step may be difficult at first. If you are using the closed-mouth method and you see a fine mist coming from your mouth or nose, the inhaler is not being used correctly.
    • Hold your breath as long as you can up to 10 seconds. This gives the medicine time to settle in your airways and lungs.
    • Take the mouthpiece away from your mouth and breathe out slowly.
    • If your doctor has told you to inhale more than 1 puff of medicine at each dose, gently shake the inhaler again, and take the next puff, following exactly the same steps you used for the first puff. Press the canister one time for each puff of medicine.
    • When you are finished, wipe off the mouthpiece and replace the cap.
    • Your doctor, nurse, or pharmacist may want you to use a spacer device with the inhaler. A spacer helps get the medicine into the lungs and reduces the amount of medicine that stays in your mouth and throat.
      • To use a spacer device with the inhaler:
        • Attach the spacer to the inhaler according to the manufacturer’s directions. There are different types of spacers available, but the method of breathing remains the same with most spacers.
        • Gently shake the inhaler and spacer three or four times.
        • Hold the mouthpiece of the spacer away from your mouth and breathe out slowly to the end of a normal breath.
        • Place the mouthpiece into your mouth between your teeth and over your tongue with your lips closed around it.
        • Press down on the canister top once to release 1 puff of medicine into the spacer. Within one or two seconds, start to breathe in slowly through your mouth for 3 to 5 seconds. Count the seconds while inhaling. Do not breathe in through your nose.
        • Hold your breath as long as you can up to 10 seconds.
        • Breathe out slowly. Do not remove the mouthpiece from your mouth. Breathe in and out slowly two or three times to make sure the spacer device is emptied.
        • If your doctor has told you to take more than 1 puff of medicine at each dose, gently shake the inhaler and spacer again and take the next puff, following exactly the same steps you used for the first puff. Do not spray more than 1 puff at a time into the spacer.
        • When you are finished, remove the spacer device from the inhaler and replace the cover of the mouthpiece.
    • Clean the inhaler mouthpiece, and spacer at least once a week.
      • To clean the inhaler:
        • Remove the canister from the inhaler and set the canister aside.
        • Wash the mouthpiece, cap, and spacer with warm, soapy water. Then, rinse well with warm, running water.
        • Shake off the excess water and let the inhaler parts air-dry completely before putting the inhaler back together.
    • Check with your pharmacist to see if you should save the inhaler piece that comes with this medicine after the medicine is used up. Refill units may be available at a lower cost. However, remember that the inhaler is meant to be used only for the medicine that comes with it. Do not use the inhaler for any other inhalation aerosol medicine, even if the cartridge fits.

For patients using beclomethasone capsules for inhalation:

  • Do not swallow the capsules. The medicine will not work if you swallow it.
  • To load the inhaler:
    • Make sure your hands are clean and dry.
    • Do not insert the capsule into the inhaler until just before you are ready to use this medicine.
    • Take the inhaler from its container. Hold the inhaler by the mouthpiece and twist the barrel in either direction until it stops.
    • Take a capsule from its container. Hold the inhaler upright with the mouthpiece pointing downward. Press the capsule, with the clear end first, firmly into the raised small hole.
    • Make sure the top of the capsule is even with the top of the hole. This will push the old used capsule shell, if there is one, into the inhaler.
    • Hold the inhaler on its side with the white dot facing up. Twist the barrel quickly until it stops. This will break the capsule into two halves so the powder can be inhaled.
  • To use the inhaler:
    • Hold the inhaler away from your mouth and breathe out slowly to the end of a normal breath.
    • Keep the inhaler on its side and place the mouthpiece in your mouth. Close your lips around it, and tilt your head slightly back. Do not block the mouthpiece with your teeth or tongue
    • Breathe in slowly through your mouth until you have taken a full deep breath.
    • Take the inhaler from your mouth and hold your breath as long as you can up to 10 seconds. This gives the medicine time to settle in your airways and lungs.
    • Hold the inhaler well away from your mouth and breathe out to the end of a normal breath.
    • If your doctor has told you to use a second capsule, follow the same steps you used for the first capsule.
    • When you have finished using the inhaler, pull the two halves of the inhaler apart and throw away the empty capsule shells. There is no need to remove the shell left in the small hole, except before cleaning.
    • Put the two halves of the inhaler back together again and place it into its container to keep it clean.
  • To clean the inhaler:
    • Every two weeks, take the inhaler apart and wash the two halves of the inhaler in clean, warm water. Make sure the empty capsule shell is removed from the small raised hole.
    • Shake out the excess water.
    • Allow all parts of the inhaler to dry before you put it back together.
    • The inhaler should be replaced every 6 months.

For patients using beclomethasone powder for inhalation:

  • To load the inhaler:
    • Make sure your hands are clean and dry.
    • Do not insert the cartridge until just before you are ready to use this medicine.
    • Take off the dark brown mouthpiece cover and make sure the mouthpiece is clean.
    • Hold the white cartridge by the exposed corners and gently pull it out until you see the ribbed sides of the cartridge.
    • Squeeze the ribbed sides and take out the cartridge unit from the body of the inhaler.
    • Place the disk containing the medicine onto the white wheel with the numbers facing up. Allow the underside of the disk to fit into the holes of the wheel.
    • Slide the cartridge unit with wheel and disk back into the body of the inhaler. Gently push the cartridge in and pull it out again. The disk will turn.
    • Continue to turn the disk in this way until the number 8 appears in the side indicator window. Each disk has eight blisters containing the medicine. The window will display how many doses you have left after you use it each time, by counting down from 8. For example, when you see the number 1, you have one dose left.
    • To replace the empty disk with a full disk, follow the same steps you used to load the inhaler. Do not throw away the wheel when you discard the empty disk.
  • To use the inhaler:
    • Hold the inhaler flat in your hand. Lift the rear edge of the lid until it is fully upright.
    • The plastic needle on the front of the lid will break the blister containing one inhalation of medicine. When the lid is raised as far as it will go, both the upper and the lower surfaces of the blister will be pierced. Do not lift the lid if the cartridge is not in the inhaler. Doing this will break the needle and you will need a new inhaler.
    • Raise the inhaler to your mouth, and place the mouthpiece in your mouth.
    • Close your lips around the mouthpiece and tilt your head slightly back. Do not block the mouthpiece with your teeth or tongue. Do not cover the air holes on the side of the mouthpiece.
    • Breathe in through your mouth as fast as you can until you have taken a full deep breath.
    • Hold your breath and remove the mouthpiece from your mouth. Continue holding your breath as long as you can up to 10 seconds before breathing out. This gives the medicine time to settle in your airways and lungs.
    • Hold the inhaler well away from your mouth and breathe out to the end of a normal breath.
    • Prepare the cartridge for your next inhalation. Pull the cartridge out once and push it in once. The disk will turn to the next numbered dose as seen in the indicator window. Do not pierce the blister until just before the inhalation.
  • To clean the inhaler:
    • Brush away the loose powder each day with the brush provided.
    • The inhaler should be replaced every 6 months.

For patients using budesonide powder for inhalation

  • To prime the inhaler:
    • Unscrew the cover of the inhaler and lift it off.
    • Hold the inhaler upright with the brown piece pointing downward. Turn the brown piece of the inhaler in one direction as far as it will go. Then twist it back until it clicks. Repeat this step one more time and the inhaler will be primed.
    • Prime each new inhaler before using it the first time. After it has been primed, it is not necessary to prime it again, even if you put it aside for a long period of time
  • To load the inhaler:
    • Unscrew the cover of the inhaler and lift it off.
    • Hold the inhaler upright with the brown piece pointing downward. Turn the brown piece of the inhaler in one direction as far as it will go. Then twist it back until it clicks.
  • To use the inhaler:
    • Hold the inhaler away from your mouth and breathe out slowly to the end of a normal breath.
    • Place the mouthpiece in your mouth and close your lips around it. Tilt your head slightly back. Do not block the mouthpiece with your teeth or tongue.
    • Breathe in quickly and evenly through your mouth until you have taken a full deep breath.
    • Hold your breath and remove the inhaler from your mouth. Continue holding your breath as long as you can up to 10 seconds before breathing out. This gives the medicine time to settle in your airways and lungs.
    • Hold the inhaler well away from your mouth and breathe out to the end of a normal breath.
    • Replace the cover on the mouthpiece to keep it clean.
  • This inhaler delivers the medicine as a very fine powder. You may not taste, smell, or feel this medicine.
  • This inhaler should not be used with a spacer.
  • When the indicator window begins to show a red mark, there are about 20 doses left. When the red mark covers the window, the inhaler is empty.

For patients using budesonide suspension for inhalation:

  • This medicine is to be used in a power-operated nebulizer equipped with a face mask or mouthpiece. Your doctor will advise you on which nebulizer to use. Make sure you understand how to use the nebulizer. If you have any questions about this, check with your doctor.
  • Any opened ampul should be protected from light. The medicine in an open ampul must be used promptly after the ampul is opened. Ampuls should be used within 2 weeks after the envelope containing them is opened.
  • To prepare the medicine for use in the nebulizer:
    • Remove one ampul from the sheet of five units and shake it gently.
    • Hold the ampul upright. Open it by twisting off the wing.
    • Squeeze the contents of the ampul into the cup of the nebulizer. If you use only half of the contents of an ampul, add enough of the sodium chloride solution provided to dilute the solution.
    • Gently shake the nebulizer. Then attach the face mask to the nebulizer and connect the nebulizer to the air pump.
  • To use the medicine in the nebulizer:
    • This medicine should be inhaled over a period of 10 to 15 minutes.
    • Breathe slowly and evenly, in and out, until no more mist is left in the nebulizer cup.
    • Rinse your mouth when you are finished with the treatment. Wash your face if you used a face mask.
  • To clean the nebulizer:
    • After each treatment, wash the cup of the nebulizer and the mask or mouthpiece in warm water with a mild detergent.
    • Allow the nebulizer parts to dry before putting them back together again.

Generic Name: Beclomethasone (Oral Inhalation) (be kloe METH a sone)
Brand Name: Qvar RediHaler, Qvar

Medically reviewed by Drugs.com. Last updated on Jul 26, 2019.

  • Overview
  • Side Effects
  • Dosage
  • Professional
  • Interactions
  • More

Uses of Qvar:

  • It is used to treat asthma.
  • Do not use Qvar (beclomethasone (oral inhalation)) to treat an asthma attack. Use a rescue inhaler. Talk with your doctor.

What do I need to tell my doctor BEFORE I take Qvar?

  • If you have an allergy to beclomethasone or any other part of Qvar (beclomethasone (oral inhalation)).
  • If you are allergic to any drugs like this one, any other drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.

This is not a list of all drugs or health problems that interact with Qvar (beclomethasone (oral inhalation)).

Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take Qvar (beclomethasone (oral inhalation)) with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.

What are some things I need to know or do while I take Qvar?

  • Tell all of your health care providers that you take Qvar (beclomethasone (oral inhalation)). This includes your doctors, nurses, pharmacists, and dentists.
  • Call your doctor right away if your breathing problems get worse, if your rescue inhaler does not work as well, or if you need to use your rescue inhaler more often.
  • If you have been taking Qvar (beclomethasone (oral inhalation)) for many weeks, talk with your doctor before stopping. You may want to slowly stop Qvar (beclomethasone (oral inhalation)).
  • You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.
  • Chickenpox and measles can be very bad or even deadly in some people taking steroid drugs like Qvar (beclomethasone (oral inhalation)). Avoid being near anyone with chickenpox or measles if you have not had these health problems before. If you have been exposed to chickenpox or measles, talk with your doctor.
  • When changing from an oral steroid to another form of a steroid, there may be very bad and sometimes deadly side effects. Signs like weakness, feeling tired, dizziness, upset stomach, throwing up, not thinking clearly, or low blood sugar may happen. Call your doctor right away if you have any of these signs. If you have a bad injury, have surgery, or any type of infection, you may need extra doses of oral steroids. These extra steroids will help your body deal with these stresses. Carry a warning card saying that there may be times when you may need extra steroids.
  • Long-term use may raise the chance of cataracts or glaucoma. Talk with the doctor.
  • Have your eye pressure checked if you are on Qvar (beclomethasone (oral inhalation)) for a long time. Talk with your doctor.
  • This medicine may cause weak bones (osteoporosis) with long-term use. Talk with your doctor to see if you have a higher chance of weak bones or if you have any questions.
  • Have a bone density test as you have been told by your doctor. Talk with your doctor.
  • Talk with your doctor before getting any vaccines. Use of some vaccines with Qvar (beclomethasone (oral inhalation)) may either raise the chance of an infection or make the vaccine not work as well.
  • This medicine may affect growth in children and teens in some cases. They may need regular growth checks. Talk with the doctor.
  • Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using Qvar (beclomethasone (oral inhalation)) while you are pregnant.
  • Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.

How is this medicine (Qvar) best taken?

Use Qvar (beclomethasone (oral inhalation)) as ordered by your doctor. Read all information given to you. Follow all instructions closely.

  • To gain the most benefit, do not miss doses.
  • Keep using Qvar (beclomethasone (oral inhalation)) as you have been told by your doctor or other health care provider, even if you feel well.
  • For breathing in only.
  • If Qvar (beclomethasone (oral inhalation)) gets in the eyes, rinse with a lot of water. If eye irritation lasts for a while, talk with the doctor.
  • Do not shake the inhaler before use. Do not shake with the cap open. This may cause the drug to be released before you are ready to take it.
  • Some products need to be primed before first use, or if they are not used for a period of time. Some products do not need to be primed. Check with the doctor or pharmacist to see if your inhaler needs to be primed.
  • Rinse out mouth after each use. Do not swallow the rinse water. Spit it out.
  • Some products may be used with a spacer. Some products must not be used with a spacer. If you are not sure about your inhaler, check with the doctor or pharmacist.
  • Clean mouthpiece by wiping with a dry tissue or cloth. Do not wash or put in water.
  • Do not use near an open flame or while smoking. It may burst.
  • Some inhalers have a dose counter to keep track of how many doses are left. If your inhaler has a dose counter, throw the inhaler away when the dose counter has a 0 in it.
  • Put the cap back on after you are done using your dose.

What do I do if I miss a dose?

  • Use a missed dose as soon as you think about it.
  • If it is close to the time for your next dose, skip the missed dose and go back to your normal time.
  • Do not use 2 doses at the same time or extra doses.

What are some side effects that I need to call my doctor about right away?

WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:

  • Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.
  • Signs of infection like fever, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, or wound that will not heal.
  • Signs of a weak adrenal gland like a very bad upset stomach or throwing up, very bad dizziness or passing out, muscle weakness, feeling very tired, mood changes, not hungry, or weight loss.
  • Redness or white patches in mouth or throat.
  • Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped Qvar (beclomethasone (oral inhalation)).
  • Change in eyesight.
  • This medicine can cause very bad breathing problems right after you take a dose. Sometimes, this may be life-threatening. If you have trouble breathing, breathing that is worse, wheezing, or coughing after using Qvar (beclomethasone (oral inhalation)), use a rescue inhaler and get medical help right away.

What are some other side effects of Qvar?

All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:

  • Headache.
  • Nose or throat irritation.
  • Signs of a common cold.

These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at http://www.fda.gov/medwatch.

If OVERDOSE is suspected:

If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened.

How do I store and/or throw out Qvar?

  • Store at room temperature. Do not freeze.
  • Protect from heat and sunlight. Do not puncture or burn even if it seems empty.
  • Throw away the inhaler after the most number of sprays have been used, even if it feels like there is more drug in the can.
  • Keep all drugs in a safe place. Keep all drugs out of the reach of children and pets.
  • Throw away unused or expired drugs. Do not flush down a toilet or pour down a drain unless you are told to do so. Check with your pharmacist if you have questions about the best way to throw out drugs. There may be drug take-back programs in your area.

Consumer information use

  • If your symptoms or health problems do not get better or if they become worse, call your doctor.
  • Do not share your drugs with others and do not take anyone else’s drugs.
  • Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.
  • Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.
  • Some drugs may have another patient information leaflet. Check with your pharmacist. If you have any questions about Qvar (beclomethasone (oral inhalation)), please talk with your doctor, nurse, pharmacist, or other health care provider.
  • If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

More about Qvar (beclomethasone)

  • Side Effects
  • During Pregnancy or Breastfeeding
  • Dosage Information
  • Drug Interactions
  • Support Group
  • En Español
  • 60 Reviews
  • Drug class: inhaled corticosteroids
  • Qvar
  • Qvar (Advanced Reading)

Other brands: Qvar RediHaler, Beclovent

  • QVAR (AHFS Monograph)
  • … +1 more
  • Bronchitis
  • Asthma, Maintenance

Qvar Side Effects

Generic Name: beclomethasone

Medically reviewed by Drugs.com. Last updated on Dec 3, 2018.

  • Overview
  • Side Effects
  • Dosage
  • Professional
  • Interactions
  • More

Note: This document contains side effect information about beclomethasone. Some of the dosage forms listed on this page may not apply to the brand name Qvar.

For the Consumer

Applies to beclomethasone: inhalation aerosol liquid

Along with its needed effects, beclomethasone (the active ingredient contained in Qvar) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking beclomethasone:

More common

  • Body aches or pain
  • congestion
  • cough
  • difficulty with breathing
  • dryness or soreness of the throat
  • fever
  • hoarseness
  • runny nose
  • tender, swollen glands in the neck
  • trouble swallowing
  • voice changes

Incidence not known

  • Attack, assault, or force
  • blindness
  • blurred vision
  • changes in behavior
  • chills
  • darkening of the skin
  • decreased vision
  • diarrhea
  • dizziness
  • eye pain
  • fainting
  • headache
  • loss of appetite
  • lower back or side pain
  • mental depression
  • nausea
  • painful or difficult urination
  • skin rash
  • sore mouth or tongue
  • tearing
  • thoughts of killing oneself
  • unusual tiredness or weakness
  • vomiting
  • white patches in the mouth or on the tongue

Some side effects of beclomethasone may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

  • Cramps
  • heavy bleeding
  • pain
  • pain or tenderness around the eyes and cheekbones
  • stuffy or runny nose
  • tightness of the chest

For Healthcare Professionals

Applies to beclomethasone: compounding powder, inhalation aerosol, inhalation aerosol with adapter

General

The most commonly reported adverse reactions have included headache, pharyngitis, rhinitis, inhalation site and taste sensation.

Endocrine

Oral therapy:

Following 4 weeks of oral therapy for ulcerative colitis, a reduction of plasma cortisol levels has been observed in up to 25% of patients; HPA-axis function recovery is expected to be transient, however follow up data is lacking.

Common (1% to 10%): Dysmenorrhea

Uncommon (0.1% to 1%): Menorrhagia

Very rare (less than 0.01%): Adrenal suppression, Cushing syndrome, cushingoid features

Respiratory

Very common (10% or more): Pharyngitis (up to 27%)

Common (1% to 10%): Rhinitis, hoarseness, throat irritation, upper respiratory tract infection, dysphonia

Uncommon (0.1% to 1%): Bronchitis, coughing, epistaxis

Rare (0.01% to 0.1%): Acute asthma episode, hemoptysis, respiratory disorder, sinusitis

Very rare (less than 0.01%): Paradoxical bronchospasm with wheezing

Frequency not reported: Eosinophilic pneumonia

Gastrointestinal

Common (1% to 10%): Oral candidiasis of mouth and throat

Uncommon (0.1% to 1%): Abdominal pain, constipation

Rare (0.01% to 0.1%): Dyspepsia, unspecified gastrointestinal disorders, nausea, tongue discoloration, toothache

Hypersensitivity

Uncommon (0.1% to 1%): Hypersensitivity reactions including rashes, urticaria, pruritus, erythema

Very rare (less than 0.01%): Hypersensitivity reactions including edema of the eyes, face, lips, and throat (angioedema), anaphylaxis and anaphylactoid reactions

Ocular

Frequency not reported: Glaucoma, cataracts

Postmarketing reports: Blurred vision, central serous chorioretinopathy

Psychiatric

Uncommon (0.1% to 1%): Anxiety

Rare (0.01% to 0.1%): Depression, insomnia, sleep disorders, hyperactivity, aggression, irritability (mostly in children)

Postmarketing reports: Suicidal ideation

Nervous system

Very common (10% or more): Headache (up to 25%)

Uncommon (0.1% to 1%): Dizziness, dysphonia, migraine

Rare (0.01% to 0.1%): Neuropathy, tremor, vertigo

Dermatologic

Uncommon (0.1% to 1%): Rash, purpura

Rare (0.01% to 0.1%): Photosensitivity reaction, skin disorder, urticaria

Frequency not reported: Easy bruising, skin thinning

Musculoskeletal

Uncommon (0.1% to 1%): Myalgia, muscle cramps, back pain

Very rare (less than 0.01%): Growth retardation, decrease in bone mineral density

Cardiovascular

Uncommon (0.1% to 1%): Chest pain, edema

Rare (0.01% to 0.1%): Hypertension, palpitations, angina pectoris

Local

Common (1% to 10%): Inhalation site sensation and taste sensation

Metabolic

Uncommon (0.1% to 1%): Increased weight

1. Cerner Multum, Inc. “UK Summary of Product Characteristics.” O 0

2. Cerner Multum, Inc. “Australian Product Information.” O 0

3. “Product Information. Qvar (beclomethasone).” Teva Pharmaceuticals USA, North Wales, PA.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer

Steroid Side Effects in Kids

Q6. I have been taking Advair for two years for asthma, but with all the added side effects of eye problems and bone density, I am reluctant to continue. In the last six months I only use it when I start wheezing a little bit. I know I am supposed to take it twice a day, but I am able to control my asthma this way. Any suggestions?

Advair (fluticasone and salmeterol) combines an inhaled corticosteroid with a long-acting bronchodilator. Inhaled steroids like Advair are quite safe. That being said, there is still concern about side effects like bone thinning and vision problems. It is recommended that patients treated with inhaled steroids get adequate calcium intake, exercise regularly and get annual eye exams and bone density evaluations.

You may be able to get by on a lower dose of inhaled steroids, but it’s important to do this in consultation with your treating physician.

Q7. My 10-year-old daughter is was taking 5 ml of Singulair (montelukast), but when I saw that it causes suicidal tendencies, I decided to stop it. Now she only takes an albuterol inhaler upon physical activity. Her asthma seems to get worse during this time of year. My pediatric pulmonologist recommended that she go on Pulmicort (budesonide) and Symbicort (budesonide and formoterol). I am not comfortable giving her an inhaled steroid due to possible side effects that may occur. Can you please recommend alternative treatments that will decrease her chance of having an asthma attack? Any information to guide me would be greatly appreciated.

Contrary to popular belief, inhaled steroids are safe, as evidenced by long-term prospective studies following Scandinavian children treated 30 years ago with inhaled steroids who are now normal, functioning adults.

It is interesting that your child is symptomatic during the pollen season. Has she been evaluated for allergy? Perhaps aggressive treatment of her allergy with antihistamines and allergy shots would alleviate many of the symptoms.

That being said, if you are not comfortable with Singulair or inhaled steroids, you could try a cromolyn inhaler as a way to control her airway inflammation. Cromolyn is not a steroid; it works by preventing the release of histamine from mast cells.

Q8. My pulmonologist can’t get me off prednisone. He has tried several different ways. When I get to a certain dosage, then my asthma begins to flare up. Is there some supplement or food that I could take that would help?

There is no evidence that food supplements help control the chronic symptoms of asthma. If one is not able to get off corticosteroids, then the most important thing to do is make sure there is not another problem contributing to the asthma-like symptoms.

Q9. My cousin has been taking prednisone for 30 years to suppress his asthma. However, the side effects are numerous and drastic. His immune system is not working, his skin has darkened, he has developed osteoporosis, and he has broken several bones. During this time period he has also developed diabetes , arthritis and other ailments. I am very concerned as to why the doctor keeps prescribing this medicine that is obviously hurting him. He has severe asthma, but surely there is a less harmful remedy. Please, do you have any suggestions and/or alternatives to this deadly drug?

Your description of your cousin accurately portrays the worst case scenario of a patient on long-term steroids. It would be prudent for any patient like this to be evaluated by an allergist who can review his medical history and conduct a physical exam, skin testing, spirometry and chest X-ray.

If possible, reducing and then stopping the steroids would be ideal, but this must be done very slowly, since prednisone has been used for a prolonged period of time. Chances are that a combination of medications will be needed to treat this severe form of asthma. This may include inhaled steroids, a long-acting bronchodilator, a leukotriene receptor antagonist, omalizumab (Xolair) and making changes to his environment.

Learn more in the Everyday Health Asthma Center.

About the author

Leave a Reply

Your email address will not be published. Required fields are marked *